Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Johnson & Johnson (NYSE: JNJ) reported third-quarter earnings of $2.12 per share on Tuesday, beating the $2 Street estimate.

Johnson & Johnson Trades Higher On Q3 Beat-And-Raise, Despite Legal Entanglements

Johnson & Johnson  on Tuesday boosted its full-year adjusted profit forecast, as multi-billion dollar sales of its cancer drugs Darzalex and Imbruvica helped it beat estimates for third-quarter profit.

J&J bumps up full-year profit view on strength of cancer drugs

Johnson & Johnson earnings and revenue unexpectedly rose in Q3. JNJ stock climbed early Tuesday, but the Dow Jones component is well off highs.

Johnson & Johnson Earnings, Sales Unexpectedly Rise; JNJ Stock Rises

Johnson & Johnson shares JNJ, -0.46% rose 1.6% in premarket trade Tuesday, after the consumer and health care giant beat earnings expectations for the third quarter.

Johnson & Johnson shares rise after earnings beat estimates, company raises guidance

Johnson & Johnson  on Tuesday posted a 22.9% rise in third-quarter profit, boosted by demand for its cancer drugs Darzalex and Imbruvica.

Johnson & Johnson posts 23% rise in third-quarter profit

J&J's pharmaceutical business, which accounts for half of the company's revenue, posted revenue of $10.88 billion.

J&J beats third-quarter earnings expectations on higher prescription drug sales

Johnson & Johnson (JNJ) is set to report their third quarter results as pending lawsuits loom over the company.

Johnson & Johnson's (JNJ) Legal Problems Continue to Worry Investors

Johnson and Johnson stock still significantly undervalued. JNJ has the financial strength to cover capital returns and any legal settlements.

Johnson and Johnson Stock Still Significantly Undervalued

Johnson & Johnson (NYSE: JNJ) is scheduled to report its most recent quarterly results before the markets open on Tuesday.

What to Expect When Johnson & Johnson Reports Tuesday

Johnson & Johnson (JNJ) generates income from three key segments, including pharmaceuticals, medical devices, and consumer products.

Johnson & Johnson's 3 Most Profitable Lines of Business (JNJ)

Citigroup

Goldman Sachs

JPMorgan Chase & Co

UnitedHealth Group

Major Banks To Flood Wall Street with Earnings Data

We may expect lower trading volume overall today, largely due to the heavy reportage of Q3 earnings beginning promptly tomorrow morning.

Bank Holiday Ahead of Q3 Earnings, Trade Negotiations

Does this mean anything for the pharmaceutical giant's long-term outlook?

Johnson & Johnson Settles Ohio Opioid Cases For $20.4 Million To Avoid Federal Trial

Gilead Sciences

Which stock wins in a battle between these two big drugmakers?

Better Buy: Gilead Sciences vs. Johnson & Johnson

At least one analyst believes Johnson & Johnson's legal liabilities are vastly overstated.

Johnson & Johnson Stock Upgraded Despite $8 Billion Risperdal Verdict: What You Need to Know

Johnson & Johnson stock offers investors some good and some bad. Should you buy or sell?

Johnson & Johnson Stock Has Limited Upside

Bernstein upgraded shares of Johnson & Johnson to an outperform rating based on the expectation that the company will settle its ongoing legal battles.

Bernstein upgrades J&J, says valuation is 'historically cheap'

Pfizer

Walgreens

Health Care Select Sector SPDR Fund

The stock market is having a banner year, despite the trade war with China and worries about a looming economic slowdown. But health care stocks aren't taking part in the rally.

Glum days have arrived for health care stocks

Archer-Daniels-Midland Company

Cardinal Health

Caterpillar

Genuine Parts

AT&T

Investors planning for retirement have a significant challenge on their hands, which is to generate enough income to maintain their desired lifestyle, explains Ben Reynolds, a leading specialist on income, a contributor to MoneyShow.com and the editor of Sure Dividend.

7 Safe Dividend Aristocrats For Growing Retirement Income

Johnson & Johnson  shares were off more than 2% on Wednesday, a day after a U.S. jury said it must pay $8 billion in punitive damages to a plaintiff in a case involving its anti-psychotic drug Risperdal, a penalty the company and others are confident will not stand.

J&J shares fall but $8 billion jury award likely to be slashed

Johnson & Johnson (JNJ) is going to have to pay a man $8 billion following a lawsuit for one of its drugs that caused him to grow breasts.
The post Jury: JNJ Must Pay $8 Billion Over Male Breast Growth Tied to Risperdal Drug appeared first on InvestorPlace.

Jury: JNJ Must Pay $8 Billion Over Male Breast Growth Tied to Risperdal Drug

The announcement that a jury has awarded $8 billion in damages to a man accusing Johnson & Johnson (NYSE: JNJ) of failing to warn about the side effects of one of its antipsycotic drugs had the drugmaker’s share price lower on Wednesday.

Johnson & Johnson Has a Lot on Its Hands After $8 Billion Court Ruling

JNJ stock slipped Wednesday after a jury ruled the Dow Jones pharmaceutical company must pay $8 billion after its antipsychotic drug, Risperdal, caused male teens to develop breast tissue.
The post Pharma Giant J&J Dips On $8 Billion Verdict Over Antipsychotic Drug appeared first on Investor's Business Daily.

Pharma Giant J&J Dips On $8 Billion Verdict Over Antipsychotic Drug

Philadelphia jury orders J&J (JNJ) to pay punitive damages of $8 billion to a man who claims that the use of Risperdal caused him to develop breasts.

J&J Ordered by Philadelphia Jury to Pay $8B in Risperdal Case

Shares of Johnson & Johnson dipped 2% on Wednesday after a jury awarded $8 billion in punitive damages to a man who accused the drugmaker of failing to warn that young men using its antipsychotic drug Risperdal could grow breasts.

News for Johnson & Johnson Stock (JNJ)